



Voyager Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares

November 16, 2015

CAMBRIDGE, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of \$14.00 per share, including 750,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Voyager Therapeutics. The gross proceeds from the initial public offering were \$80,500,000, before underwriting discounts and commissions and estimated offering expenses. Voyager Therapeutics' common stock is listed on the NASDAQ Global Select Market under the ticker symbol "VYGR."

Cowen and Company and Piper Jaffray & Co. acted as joint book-running managers for the offering. Wedbush PacGrow and Nomura acted as co-managers for the offering.

A registration statement relating to these securities was filed with, and was declared effective by, the Securities and Exchange Commission on November 10, 2015. Copies of the registration statement can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov. This offering was made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to the offering was filed with the Securities and Exchange Commission and may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (631) 274-2806, or by fax at (631) 254-7140, and from Piper Jaffray & Co. by mail at Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: Investor Relations:

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
Sarah@sternir.com

Media:

Katie Engleman
Pure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com

Voyager Therapeutics, Inc.